- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Vitrafy Life Sciences Enters US Cell and Gene Therapy Space with Cryopreservation Agreement | 1 | smallcaps.com.au | ||
| VITRAFY LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| Mi | VITRAFY LIFE SCIENCES LIMITED: Vitrafy enters U.S. Cell & Gene Therapy Market | 1 | ASX | ||
| 04.08. | Vitrafy FY26 slides: blood crisis drives partnerships, FDA filing ahead | 1 | Investing.com | ||
| 04.08. | Vitrafy FY2026 slides: blood crisis fuels commercial momentum | 2 | Investing.com | ||
| 04.08. | VITRAFY LIFE SCIENCES LIMITED: FY26 Appendix 4G | 1 | ASX | ||
| 04.08. | VITRAFY LIFE SCIENCES LIMITED: FY26 Full Year Results Presentation | 2 | ASX | ||
| 04.08. | VITRAFY LIFE SCIENCES LIMITED: FY26 Corporate Governance Statement | 1 | ASX | ||
| 04.08. | VITRAFY LIFE SCIENCES LIMITED: FY26 Appendix 4E and Annual Report | 2 | ASX | ||
| 03.08. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy FY26 Investor Briefing | 1 | ASX | ||
| 28.07. | VITRAFY LIFE SCIENCES LIMITED: Q4 FY26 Quarterly Activities Report and Appendix 4C | - | ASX | ||
| 23.07. | Health Check: Vitrafy addresses looming US platelet shortage with US blood bank collab | 1 | Stockhead | ||
| 23.07. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy enters a partnership with Hoxworth Blood Center | - | ASX | ||
| 22.07. | VITRAFY LIFE SCIENCES LIMITED: Application for quotation of securities - VFY | - | ASX | ||
| 13.07. | VITRAFY LIFE SCIENCES LIMITED: Notification of cessation of securities - VFY | - | ASX | ||
| 10.07. | VITRAFY LIFE SCIENCES LIMITED: Application for quotation of securities - VFY | - | ASX | ||
| 09.07. | VITRAFY LIFE SCIENCES LIMITED: Change of Director's Interest Notice - Correction | - | ASX | ||
| 09.07. | VITRAFY LIFE SCIENCES LIMITED: Change of Director's Interest Notices | 1 | ASX | ||
| 09.07. | VITRAFY LIFE SCIENCES LIMITED: Application for quotation of securities - VFY | - | ASX | ||
| 08.07. | VITRAFY LIFE SCIENCES LIMITED: Expiry of Voluntary Escrow Restrictions | - | ASX | ||
| 08.07. | VITRAFY LIFE SCIENCES LIMITED: Results of Oversubscribed Share Purchase Plan | - | ASX |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 15,170 | -0,65 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,600 | -0,03 % | Summit Therapeutics Stock Rises 11% | ||
| QIAGEN | 37,435 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| TARSUS PHARMACEUTICALS | 90,84 | +0,07 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| TYRA BIOSCIENCES | 28,650 | 0,00 % | Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug | ||
| RECURSION PHARMACEUTICALS | 3,635 | +0,14 % | Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? | ||
| PRAXIS PRECISION MEDICINES | 352,42 | +0,17 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VIR BIOTECHNOLOGY | 11,385 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| VERA THERAPEUTICS | 35,890 | 0,00 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| MODERNA | 125,24 | -0,03 % | BioNTech Aktie: Nach dem Moderna-Rausch folgt der Kater | Bei der BioNTech Aktie ging es in den vergangenen Tagen wild zu. Erst schwamm das an der NASDAQ notierte Papier auf der Welle positiver Moderna-Nachrichten nach oben und fuhr hohe Gewinne ein, dann... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,270 | -0,04 % | Dyne to present preclinical data on four DMD therapies | ||
| RELAY THERAPEUTICS | 19,060 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,48 | +0,08 % | Can KT-621 Mark a Turning Point for Kymera Therapeutics? | ||
| ALUMIS | 11,090 | -0,09 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 34,140 | +0,12 % | Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? |
Das Unternehmen VITRAFY LIFE SCIENCES LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITRAFY LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.